Generic Name and Formulations:
Lorcaserin HCl 10mg; tabs.
Indications for BELVIQ:
As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 or ≥27kg/m2 in the presence of at least one weight-related comorbidity (eg, hypertension, dyslipidemia, type 2 diabetes).
Limitations Of use:
Safety and efficacy of coadministration with other weight loss products (eg, phentermine, OTC drugs, herbal preps) have not been established. Effect on cardiovascular morbidity and mortality has not been established.
Max: 10mg twice daily. Evaluate weight loss after 12 weeks. Discontinue if ≥5% weight loss is not achieved.
<18yrs: not recommended.
Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs/symptoms; discontinue and treat if occur. CHF. Risk of valvular heart disease; evaluate and consider discontinuing if signs/symptoms occur. Bradycardia or >1st degree heart block. Monitor for depression, suicidal thoughts, and/or unusual behavioral changes; discontinue if develop. Increased risk of hypoglycemia in patients with diabetes on antidiabetic therapy; measure blood glucose prior to starting and during treatment. Predisposition to priapism. Anatomical penile deformation. Monitor CBCs periodically during therapy. Measure prolactin levels if elevation is suspected. Moderate renal impairment. Severe renal impairment or ESRD: not recommended. Severe hepatic impairment. Nursing mothers: not recommended.
Caution with concomitant triptans, MAOIs, linezolid, SSRIs, SNRIs, TCAs, bupropion, lithium, tramadol, tryptophan, St. John’s wort, antipsychotics, dopamine antagonists, or PDE-5 inhibitors. Potentiates dextromethorphan and other CYP2D6 substrates. Increased risk of cardiac valvulopathy with concomitant drugs that are potent 5-HT2B receptor agonists (eg, cabergoline). Concomitant insulin: not studied.
Serotonin 2C receptor agonist.
Headache, dizziness, fatigue, nausea, dry mouth, constipation, hypoglycemia, back pain, cough; cognitive impairment, bradycardia, psychiatric disorders, hematological changes, prolactin elevation.
Tabs—60; XR tabs—30
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States